Auranofin Suppresses Plasminogen Activator Inhibitor-2 Expression through Annexin A5 Induction in Human Prostate Cancer Cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Dong-Won | - |
dc.contributor.author | Kwon, Yeo-Jung | - |
dc.contributor.author | Ye, Dong-Jin | - |
dc.contributor.author | Baek, Hyoung-Seok | - |
dc.contributor.author | Lee, Joo-Eun | - |
dc.contributor.author | Chun, Young-Jin | - |
dc.date.available | 2019-03-08T09:36:04Z | - |
dc.date.issued | 2017-03 | - |
dc.identifier.issn | 1976-9148 | - |
dc.identifier.issn | 2005-4483 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/4699 | - |
dc.description.abstract | Auranofin has been developed as antirheumatic drugs, which is currently under clinical development for the treatment of chronic lymphocytic leukemia. Previous report showed that auranofin induced apoptosis by enhancement of annexin A5 expression in PC-3 cells. To understand the role of annexin A5 in auranofin-mediated apoptosis, we performed microarray data analysis to study annexin A5-controlled gene expression in annexin A5 knockdown PC-3 cells. Of differentially expressed genes, plasminogen activator inhibitor (PAI)-2 was increased by annexin A5 siRNA confirmed by qRT-PCR and western blot. Treatment with auranofin decreased PAI-2 and increased annexin A5 expression as well as promoting apoptosis. Furthermore, auranofin-induced apoptosis was recovered by annexin A5 siRNA but it was promoted by PAI-2 siRNA. Interestingly, knockdown of annexin A5 rescued PAI-2 expression suppressed by auranofin. Taken together, our study suggests that induction of annexin A5 by auranofin may enhance apoptosis through suppression of PAI-2 expression in PC-3 cells. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN SOC APPLIED PHARMACOLOGY | - |
dc.title | Auranofin Suppresses Plasminogen Activator Inhibitor-2 Expression through Annexin A5 Induction in Human Prostate Cancer Cells | - |
dc.type | Article | - |
dc.identifier.doi | 10.4062/biomolther.2016.223 | - |
dc.identifier.bibliographicCitation | BIOMOLECULES & THERAPEUTICS, v.25, no.2, pp 177 - 185 | - |
dc.identifier.kciid | ART002199208 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000395615300011 | - |
dc.identifier.scopusid | 2-s2.0-85015827685 | - |
dc.citation.endPage | 185 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 177 | - |
dc.citation.title | BIOMOLECULES & THERAPEUTICS | - |
dc.citation.volume | 25 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Annexin A5 | - |
dc.subject.keywordAuthor | Apoptosis | - |
dc.subject.keywordAuthor | Auranofin | - |
dc.subject.keywordAuthor | Plasminogen activator inhibitor-2 | - |
dc.subject.keywordPlus | CISPLATIN-INDUCED TOXICITY | - |
dc.subject.keywordPlus | FLOW-CYTOMETRIC DETECTION | - |
dc.subject.keywordPlus | PROTEIN-KINASE-C | - |
dc.subject.keywordPlus | PHOSPHATIDYLSERINE EXPRESSION | - |
dc.subject.keywordPlus | ANTICANCER ACTIVITY | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | TYPE-2 | - |
dc.subject.keywordPlus | OVEREXPRESSION | - |
dc.subject.keywordPlus | NORMALIZATION | - |
dc.subject.keywordPlus | PATTERNS | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.